Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan and Hydrochlorothiazide tablets.
The tablets are generic equivalent to Novartis Pharmaceuticals Corp’s Diovan HCT tablets.
The drug is indicated for the treatment of hypertension to lower blood pressure and falls under the cardiovascular (CVS) therapeutic category.
The market size of the product is approximately $1.7 billion for the 12 months ended September 2012, according to IMS.
The product is ready for launch, the Hyderabad-based company said in a release.